ID   GPC1_HUMAN              Reviewed;         558 AA.
AC   P35052; B3KTD1; Q53QM4;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-MAR-2010, sequence version 2.
DT   28-JUN-2023, entry version 189.
DE   RecName: Full=Glypican-1;
DE   Contains:
DE     RecName: Full=Secreted glypican-1;
DE   Flags: Precursor;
GN   Name=GPC1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 24-53; 100-118
RP   AND 298-317, GPI-ANCHOR AT SER-530, GLYCOSYLATION AT ASN-116, AND VARIANT
RP   GLY-500.
RC   TISSUE=Lung fibroblast;
RX   PubMed=2148568; DOI=10.1083/jcb.111.6.3165;
RA   David G., Lories V., Decock B., Marynen P., Cassiman J.-J.,
RA   van den Berghe H.;
RT   "Molecular cloning of a phosphatidylinositol-anchored membrane heparan
RT   sulfate proteoglycan from human lung fibroblasts.";
RL   J. Cell Biol. 111:3165-3176(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT GLY-500.
RC   TISSUE=Salivary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   COPPER-BINDING, S-NITROSYLATION, AND GLYCOSYLATION.
RX   PubMed=12732622; DOI=10.1074/jbc.m300394200;
RA   Mani K., Cheng F., Havsmark B., Jonsson M., Belting M., Fransson L.A.;
RT   "Prion, amyloid beta-derived Cu(II) ions, or free Zn(II) ions support S-
RT   nitroso-dependent autocleavage of glypican-1 heparan sulfate.";
RL   J. Biol. Chem. 278:38956-38965(2003).
RN   [7]
RP   SUBCELLULAR LOCATION, AND POSSIBLE ASSOCIATION WITH ALZHEIMER DISEASE.
RX   PubMed=15084524; DOI=10.1096/fj.03-1040fje;
RA   Watanabe N., Araki W., Chui D.H., Makifuchi T., Ihara Y., Tabira T.;
RT   "Glypican-1 as an Abeta binding HSPG in the human brain: its localization
RT   in DIG domains and possible roles in the pathogenesis of Alzheimer's
RT   disease.";
RL   FASEB J. 18:1013-1015(2004).
RN   [8]
RP   S-NITROSYLATION, AND ASSOCIATION WITH NIEMANN-PICK TYPE C1 DISEASE.
RX   PubMed=16645004; DOI=10.1093/glycob/cwj121;
RA   Mani K., Cheng F., Fransson L.A.;
RT   "Defective nitric oxide-dependent, deaminative cleavage of glypican-1
RT   heparan sulfate in Niemann-Pick C1 fibroblasts.";
RL   Glycobiology 16:711-718(2006).
RN   [9]
RP   SUBCELLULAR LOCATION, S-NITROSYLATION, AND GLYCOSYLATION.
RX   PubMed=16971378; DOI=10.1093/glycob/cwl045;
RA   Mani K., Cheng F., Fransson L.A.;
RT   "Constitutive and vitamin C-induced, NO-catalyzed release of heparan
RT   sulfate from recycling glypican-1 in late endosomes.";
RL   Glycobiology 16:1251-1261(2006).
RN   [10]
RP   GLYCOSYLATION, AND LACK OF GLYCOSYLATION AT SER-55.
RX   PubMed=19775117; DOI=10.1021/bi901402x;
RA   Svensson G., Linse S., Mani K.;
RT   "Chemical and thermal unfolding of glypican-1: protective effect of heparan
RT   sulfate against heat-induced irreversible aggregation.";
RL   Biochemistry 48:9994-10004(2009).
RN   [11]
RP   S-NITROSYLATION, SUBCELLULAR LOCATION, AND GLYCOSYLATION.
RX   PubMed=19479373; DOI=10.1007/s10719-009-9243-z;
RA   Svensson G., Mani K.;
RT   "S-Nitrosylation of secreted recombinant human glypican-1.";
RL   Glycoconj. J. 26:1247-1257(2009).
RN   [12]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19936054; DOI=10.1371/journal.ppat.1000666;
RA   Taylor D.R., Whitehouse I.J., Hooper N.M.;
RT   "Glypican-1 mediates both prion protein lipid raft association and disease
RT   isoform formation.";
RL   PLoS Pathog. 5:E1000666-E1000666(2009).
RN   [13]
RP   GLYCOSYLATION AT ASN-79 AND ASN-116, AND MUTAGENESIS OF ASN-79 AND ASN-116.
RX   PubMed=21932778; DOI=10.1021/bi200218s;
RA   Svensson G., Hyrenius Wittsten A., Linse S., Mani K.;
RT   "The structural role of N-linked glycans on human glypican-1.";
RL   Biochemistry 50:9377-9387(2011).
RN   [14]
RP   S-NITROSYLATION, GLYCOSYLATION, AND FUNCTION.
RX   PubMed=21642435; DOI=10.1074/jbc.m111.243345;
RA   Cheng F., Cappai R., Ciccotosto G.D., Svensson G., Multhaup G.,
RA   Fransson L.A., Mani K.;
RT   "Suppression of amyloid beta A11 antibody immunoreactivity by vitamin C:
RT   possible role of heparan sulfate oligosaccharides derived from glypican-1
RT   by ascorbate-induced, nitric oxide (NO)-catalyzed degradation.";
RL   J. Biol. Chem. 286:27559-27572(2011).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS), DISULFIDE BONDS, LACK OF
RP   GLYCOSYLATION AT SER-55, AND GLYCOSYLATION AT ASN-79 AND ASN-116.
RX   PubMed=22351761; DOI=10.1074/jbc.m111.322487;
RA   Svensson G., Awad W., Hakansson M., Mani K., Logan D.T.;
RT   "Crystal structure of N-glycosylated human glypican-1 core protein:
RT   Structure of two loops evolutionarily conserved in vertebrate glypican-1.";
RL   J. Biol. Chem. 287:14040-14051(2012).
RN   [16]
RP   VARIANT [LARGE SCALE ANALYSIS] ASP-337.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Cell surface proteoglycan that bears heparan sulfate. Binds,
CC       via the heparan sulfate side chains, alpha-4 (V) collagen and
CC       participates in Schwann cell myelination (By similarity). May act as a
CC       catalyst in increasing the rate of conversion of prion protein PRPN(C)
CC       to PRNP(Sc) via associating (via the heparan sulfate side chains) with
CC       both forms of PRPN, targeting them to lipid rafts and facilitating
CC       their interaction. Required for proper skeletal muscle differentiation
CC       by sequestering FGF2 in lipid rafts preventing its binding to receptors
CC       (FGFRs) and inhibiting the FGF-mediated signaling. {ECO:0000250,
CC       ECO:0000269|PubMed:19936054, ECO:0000269|PubMed:21642435}.
CC   -!- INTERACTION:
CC       P35052; Q6PRD1: GPR179; NbExp=2; IntAct=EBI-8307554, EBI-20895185;
CC       P35052; Q8C419: Gpr158; Xeno; NbExp=3; IntAct=EBI-8307554, EBI-776313;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Lipid-anchor, GPI-anchor;
CC       Extracellular side. Endosome. Note=S-nitrosylated form recycled in
CC       endosomes. Localizes to CAV1-containing vesicles close to the cell
CC       surface. Cleavage of heparan sulfate side chains takes place mainly in
CC       late endosomes. Associates with both forms of PRNP in lipid rafts.
CC       Colocalizes with APP in perinuclear compartments and with CP in
CC       intracellular compartments. Associates with fibrillar APP amyloid-beta
CC       peptides in lipid rafts in Alzheimer disease brains.
CC   -!- SUBCELLULAR LOCATION: [Secreted glypican-1]: Secreted, extracellular
CC       space.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P35052-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P35052-2; Sequence=VSP_055225, VSP_055226, VSP_055227;
CC   -!- PTM: S-nitrosylated in a Cu(2+)-dependent manner. Nitric acid (NO) is
CC       released from the nitrosylated cysteines by ascorbate or by some other
CC       reducing agent, in a Cu(2+) or Zn(2+) dependent manner. This free
CC       nitric oxide is then capable of cleaving the heparan sulfate side
CC       chains.
CC   -!- PTM: N- and O-glycosylated. N-glycosylation is mainly of the complex
CC       type containing sialic acid. O-glycosylated with heparan sulfate. The
CC       heparan sulfate chains can be cleaved either by the action of
CC       heparanase or, degraded by a deaminative process that uses nitric oxide
CC       (NO) released from the S-nitrosylated cysteines. This process is
CC       triggered by ascorbate, or by some other reducing agent, in a
CC       Cu(2+)- or Zn(2+) dependent manner. Cu(2+) ions are provided by
CC       ceruloproteins such as APP, PRNP or CP which associate with GCP1 in
CC       intracellular compartments or lipid rafts.
CC       {ECO:0000269|PubMed:12732622, ECO:0000269|PubMed:16971378,
CC       ECO:0000269|PubMed:19479373, ECO:0000269|PubMed:19775117,
CC       ECO:0000269|PubMed:2148568, ECO:0000269|PubMed:21642435,
CC       ECO:0000269|PubMed:21932778, ECO:0000269|PubMed:22351761}.
CC   -!- PTM: This cell-associated glypican is further processed to give rise to
CC       a medium-released species.
CC   -!- DISEASE: Note=Associates (via the heparan sulfate side chains) with
CC       fibrillar APP amyloid-beta peptides in primitive and classic amyloid
CC       plaques and may be involved in the deposition of these senile plaques
CC       in the Alzheimer disease (AD) brain (PubMed:15084524).
CC       {ECO:0000269|PubMed:15084524}.
CC   -!- DISEASE: Note=Misprocessing of GPC1 is found in fibroblasts of patients
CC       with Niemann-Pick Type C1 disease. This is due to the defective
CC       deaminative degradation of heparan sulfate chains (PubMed:16645004).
CC       {ECO:0000269|PubMed:16645004}.
CC   -!- SIMILARITY: Belongs to the glypican family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X54232; CAA38139.1; -; mRNA.
DR   EMBL; AK095397; BAG53043.1; -; mRNA.
DR   EMBL; AK096638; BAG53345.1; -; mRNA.
DR   EMBL; AC110619; AAY24160.1; -; Genomic_DNA.
DR   EMBL; CH471063; EAW71180.1; -; Genomic_DNA.
DR   EMBL; CH471063; EAW71183.1; -; Genomic_DNA.
DR   EMBL; BC051279; AAH51279.1; -; mRNA.
DR   CCDS; CCDS2534.1; -. [P35052-1]
DR   PIR; A36347; A36347.
DR   RefSeq; NP_002072.2; NM_002081.2. [P35052-1]
DR   PDB; 4ACR; X-ray; 2.55 A; A/B/C/D=24-479.
DR   PDB; 4AD7; X-ray; 2.94 A; A/B/C/D=24-529.
DR   PDB; 4BWE; X-ray; 2.46 A; A/B/C/D=24-479.
DR   PDB; 4YWT; X-ray; 2.38 A; A/B/C/D=24-527.
DR   PDBsum; 4ACR; -.
DR   PDBsum; 4AD7; -.
DR   PDBsum; 4BWE; -.
DR   PDBsum; 4YWT; -.
DR   AlphaFoldDB; P35052; -.
DR   SMR; P35052; -.
DR   BioGRID; 109079; 191.
DR   IntAct; P35052; 30.
DR   MINT; P35052; -.
DR   STRING; 9606.ENSP00000264039; -.
DR   GlyConnect; 1279; 2 N-Linked glycans (1 site).
DR   GlyCosmos; P35052; 6 sites, 3 glycans.
DR   GlyGen; P35052; 12 sites, 2 N-linked glycans (1 site), 3 O-linked glycans (6 sites).
DR   iPTMnet; P35052; -.
DR   PhosphoSitePlus; P35052; -.
DR   SwissPalm; P35052; -.
DR   BioMuta; GPC1; -.
DR   DMDM; 292495012; -.
DR   EPD; P35052; -.
DR   jPOST; P35052; -.
DR   MassIVE; P35052; -.
DR   MaxQB; P35052; -.
DR   PaxDb; P35052; -.
DR   PeptideAtlas; P35052; -.
DR   ProteomicsDB; 54976; -. [P35052-1]
DR   Antibodypedia; 34516; 389 antibodies from 34 providers.
DR   DNASU; 2817; -.
DR   Ensembl; ENST00000264039.7; ENSP00000264039.2; ENSG00000063660.9. [P35052-1]
DR   GeneID; 2817; -.
DR   KEGG; hsa:2817; -.
DR   MANE-Select; ENST00000264039.7; ENSP00000264039.2; NM_002081.3; NP_002072.2.
DR   UCSC; uc002vyw.5; human. [P35052-1]
DR   AGR; HGNC:4449; -.
DR   CTD; 2817; -.
DR   DisGeNET; 2817; -.
DR   GeneCards; GPC1; -.
DR   HGNC; HGNC:4449; GPC1.
DR   HPA; ENSG00000063660; Tissue enhanced (skin).
DR   MIM; 600395; gene.
DR   neXtProt; NX_P35052; -.
DR   NIAGADS; ENSG00000063660; -.
DR   OpenTargets; ENSG00000063660; -.
DR   PharmGKB; PA28830; -.
DR   VEuPathDB; HostDB:ENSG00000063660; -.
DR   eggNOG; KOG3821; Eukaryota.
DR   GeneTree; ENSGT01050000244897; -.
DR   HOGENOM; CLU_024658_2_0_1; -.
DR   InParanoid; P35052; -.
DR   OMA; YCAHCRG; -.
DR   OrthoDB; 2939408at2759; -.
DR   PhylomeDB; P35052; -.
DR   TreeFam; TF105317; -.
DR   PathwayCommons; P35052; -.
DR   Reactome; R-HSA-1971475; A tetrasaccharide linker sequence is required for GAG synthesis.
DR   Reactome; R-HSA-2022928; HS-GAG biosynthesis.
DR   Reactome; R-HSA-2024096; HS-GAG degradation.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-3560783; Defective B4GALT7 causes EDS, progeroid type.
DR   Reactome; R-HSA-3560801; Defective B3GAT3 causes JDSSDHD.
DR   Reactome; R-HSA-3656237; Defective EXT2 causes exostoses 2.
DR   Reactome; R-HSA-3656253; Defective EXT1 causes exostoses 1, TRPS2 and CHDS.
DR   Reactome; R-HSA-376176; Signaling by ROBO receptors.
DR   Reactome; R-HSA-4420332; Defective B3GALT6 causes EDSP2 and SEMDJL1.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   SignaLink; P35052; -.
DR   SIGNOR; P35052; -.
DR   BioGRID-ORCS; 2817; 14 hits in 1149 CRISPR screens.
DR   ChiTaRS; GPC1; human.
DR   GeneWiki; Glypican_1; -.
DR   GenomeRNAi; 2817; -.
DR   Pharos; P35052; Tbio.
DR   PRO; PR:P35052; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P35052; protein.
DR   Bgee; ENSG00000063660; Expressed in ventricular zone and 194 other tissues.
DR   ExpressionAtlas; P35052; baseline and differential.
DR   Genevisible; P35052; HS.
DR   GO; GO:0009986; C:cell surface; IBA:GO_Central.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; ISS:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; HDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; TAS:ProtInc.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0045121; C:membrane raft; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0045202; C:synapse; IBA:GO_Central.
DR   GO; GO:0005507; F:copper ion binding; IDA:UniProtKB.
DR   GO; GO:0017134; F:fibroblast growth factor binding; ISS:UniProtKB.
DR   GO; GO:0043236; F:laminin binding; ISS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0030200; P:heparan sulfate proteoglycan catabolic process; IDA:UniProtKB.
DR   GO; GO:0032288; P:myelin assembly; ISS:UniProtKB.
DR   GO; GO:0040037; P:negative regulation of fibroblast growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:2001016; P:positive regulation of skeletal muscle cell differentiation; ISS:UniProtKB.
DR   GO; GO:1905475; P:regulation of protein localization to membrane; IBA:GO_Central.
DR   GO; GO:0014037; P:Schwann cell differentiation; ISS:UniProtKB.
DR   InterPro; IPR001863; Glypican.
DR   InterPro; IPR019803; Glypican_CS.
DR   PANTHER; PTHR10822; GLYPICAN; 1.
DR   PANTHER; PTHR10822:SF8; GLYPICAN-1; 1.
DR   Pfam; PF01153; Glypican; 1.
DR   PROSITE; PS01207; GLYPICAN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Copper;
KW   Direct protein sequencing; Disulfide bond; Endosome; Glycoprotein;
KW   GPI-anchor; Heparan sulfate; Lipoprotein; Membrane; Proteoglycan;
KW   Reference proteome; S-nitrosylation; Secreted; Signal; Zinc.
FT   SIGNAL          1..23
FT                   /evidence="ECO:0000269|PubMed:2148568"
FT   CHAIN           24..530
FT                   /note="Glypican-1"
FT                   /id="PRO_0000012295"
FT   CHAIN           24..?
FT                   /note="Secreted glypican-1"
FT                   /id="PRO_0000333837"
FT   PROPEP          531..558
FT                   /note="Removed in mature form"
FT                   /evidence="ECO:0000305"
FT                   /id="PRO_0000012296"
FT   REGION          341..374
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          505..534
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        353..367
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   LIPID           530
FT                   /note="GPI-anchor amidated serine"
FT                   /evidence="ECO:0000305|PubMed:2148568"
FT   CARBOHYD        79
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21932778,
FT                   ECO:0000269|PubMed:22351761"
FT   CARBOHYD        116
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:2148568,
FT                   ECO:0000269|PubMed:21932778, ECO:0000269|PubMed:22351761"
FT   CARBOHYD        486
FT                   /note="O-linked (Xyl...) (heparan sulfate) serine"
FT                   /evidence="ECO:0000305"
FT   CARBOHYD        488
FT                   /note="O-linked (Xyl...) (heparan sulfate) serine"
FT                   /evidence="ECO:0000305"
FT   CARBOHYD        490
FT                   /note="O-linked (Xyl...) (heparan sulfate) serine"
FT                   /evidence="ECO:0000305"
FT   DISULFID        32..68
FT                   /evidence="ECO:0000269|PubMed:22351761"
FT   DISULFID        62..256
FT                   /evidence="ECO:0000269|PubMed:22351761"
FT   DISULFID        69..259
FT                   /evidence="ECO:0000269|PubMed:22351761"
FT   DISULFID        191..343
FT                   /evidence="ECO:0000269|PubMed:22351761"
FT   DISULFID        246..279
FT                   /evidence="ECO:0000269|PubMed:22351761"
FT   DISULFID        268..415
FT                   /evidence="ECO:0000269|PubMed:22351761"
FT   DISULFID        272..401
FT                   /evidence="ECO:0000269|PubMed:22351761"
FT   VAR_SEQ         1..72
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055225"
FT   VAR_SEQ         295..359
FT                   /note="DSMVLITDKFWGTSGVESVIGSVHTWLAEAINALQDNRDTLTAKVIQGCGNP
FT                   KVNPQGPGPEEKR -> GEPPPARAAWNCLGECTTGGPGGRVVPSLELGPRDLIRDALT
FT                   RARSGWCCRVEGPGCLLNVLSDV (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055226"
FT   VAR_SEQ         360..558
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055227"
FT   VARIANT         337
FT                   /note="A -> D (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036044"
FT   VARIANT         500
FT                   /note="S -> G (in dbSNP:rs2228331)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:2148568"
FT                   /id="VAR_033977"
FT   MUTAGEN         79
FT                   /note="N->Q: Protein yield reduced by half. Protein yield
FT                   reduced by 90%, abolishes N-glycosylation but no effect on
FT                   secondary structure; when associated with Q-116."
FT                   /evidence="ECO:0000269|PubMed:21932778"
FT   MUTAGEN         116
FT                   /note="N->Q: No effect on protein yield. Protein yield
FT                   reduced by 90%, abolishes N-glycosylation but no effect on
FT                   secondary structure; when associated with Q-79."
FT                   /evidence="ECO:0000269|PubMed:21932778"
FT   HELIX           33..40
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   TURN            41..43
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           46..48
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           56..58
FT                   /evidence="ECO:0007829|PDB:4BWE"
FT   STRAND          60..62
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   STRAND          64..68
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           71..130
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           132..135
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           138..153
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           159..178
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   STRAND          180..182
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           187..192
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   TURN            201..204
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           205..237
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           244..254
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           256..259
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           269..279
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           281..284
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           287..300
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           301..304
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   STRAND          307..310
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           313..315
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           317..329
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           332..335
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           340..343
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           374..388
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           392..403
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   STRAND          418..422
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   STRAND          431..433
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           434..436
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   STRAND          440..442
FT                   /evidence="ECO:0007829|PDB:4YWT"
FT   HELIX           451..472
FT                   /evidence="ECO:0007829|PDB:4YWT"
SQ   SEQUENCE   558 AA;  61680 MW;  16553B56080A83C8 CRC64;
     MELRARGWWL LCAAAALVAC ARGDPASKSR SCGEVRQIYG AKGFSLSDVP QAEISGEHLR
     ICPQGYTCCT SEMEENLANR SHAELETALR DSSRVLQAML ATQLRSFDDH FQHLLNDSER
     TLQATFPGAF GELYTQNARA FRDLYSELRL YYRGANLHLE ETLAEFWARL LERLFKQLHP
     QLLLPDDYLD CLGKQAEALR PFGEAPRELR LRATRAFVAA RSFVQGLGVA SDVVRKVAQV
     PLGPECSRAV MKLVYCAHCL GVPGARPCPD YCRNVLKGCL ANQADLDAEW RNLLDSMVLI
     TDKFWGTSGV ESVIGSVHTW LAEAINALQD NRDTLTAKVI QGCGNPKVNP QGPGPEEKRR
     RGKLAPRERP PSGTLEKLVS EAKAQLRDVQ DFWISLPGTL CSEKMALSTA SDDRCWNGMA
     RGRYLPEVMG DGLANQINNP EVEVDITKPD MTIRQQIMQL KIMTNRLRSA YNGNDVDFQD
     ASDDGSGSGS GDGCLDDLCS RKVSRKSSSS RTPLTHALPG LSEQEGQKTS AASCPQPPTF
     LLPLLLFLAL TVARPRWR
//
